UNSPSC 51382002: Lufuradom

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C22H20FN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GS8D070P7W, chemically known as (- )-n-((8-fluoro-2,3-dihydro-1-methyl-5-phenyl-1h-1,4-benzodiazepin-2-yl)-methyl)-3-furamide. but generally known as lufuradom, which bears US NIH Compound Identifier 3045400. European Medicines Agency schedules Lufuradom in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08617MIG.

UNSPSC 51382002 Lufuradom is a Commodity code that encompasses pharmaceutical products and related health-system supplies procured by state and local government agencies — specifically naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products distributed through public health departments, health and human services agencies, and cooperative purchasing alliances. State and local buyers under this code include county health departments, state health and human services commissions, and multi-state cooperative purchasing organizations; Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) appear as active recent buyers. Work solicited ranges from direct procurement of naloxone and drug deactivation systems for community health initiatives, to manufacturer supply agreements for generic pharmaceuticals and OTC products through established wholesaler channels, to exploratory RFIs gathering vendor capacity for direct-to-manufacturer pharmacy programs.

Recent activity spans Florida, Minnesota, Texas, and participating MMCAP jurisdictions including Oregon. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response deadline July 26, 2023. MMCAP, administered by the Minnesota Department of Administration, released an RFP on January 20, 2026 (due March 26, 2026) establishing multiple contracts for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, with awarded vendors effective July 1, 2026 and evaluation weighted 75 percent on price competitiveness. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, with no formal award or budget identified at that exploratory stage.